Shanghai Fosun Pharmaceutical (Fosun Pharma), a Chinese healthcare provider, is to acquire an 86 per cent stake in Indian generic injectable pharmaceutical products company Gland Pharma for up to USD1.26 billion.
The deal will see Fosun Pharma purchase all shares of Gland owned by KKR Floorline Investments in addition to shares purchased from other shareholders of the company.
PVN Raju, founder of Gland, and his son, Dr Ravi Penmetsa (pictured), will continue to be on the board, and Penmetsa will continue as managing director and CEO. The family will retain a stake in Gland.
Penmetsa says: "This transaction truly demonstrates the strong expertise of our people and the potential for Indian companies to improve health care in markets worldwide. We look forward to continuing our work to research, develop and provide medical products from India and continue to add capacity at our facilities.”
KKR invested in Gland in 2014. Since then, the company has seen its capacity and profit grow significantly. This was achieved, in part, by Gland’s investment into a new manufacturing plant, significant optimisation of existing facilities, enhanced R&D spend and focus, and Gland’s ability to file for and own further intellectual property.
“We have benefited from the experience of KKR, which brought the skills and expertise that enabled Gland to grow and develop as a multinational leader in health care. We achieved improved performance and look forward to building upon that foundation," Penmetsa adds.
Following the close of the transaction, Gland will remain headquartered in Hyderabad.
“With a track record of achieving greater scale, innovating world-class products and operating to global best practices, KKR takes pride in its relationship with Gland and in the company’s support of the ‘Make in India’ campaign. We are confident Fosun Pharma will experience continued success as it invests and supports Gland’s next stage of growth," says Joseph Y Bae, member of KKR and managing partner of KKR Asia.
Fosun Pharma is a researcher, developer, producer and retailer of biopharmaceutical products worldwide.
Chen Qiyu, chairman of Fosun Pharma, says: “We’re pleased to incorporate Gland into the Fosun Pharma family. Gland’s management team, along with support from KKR, has done a tremendous job in growing its business to become the global leader in the generics injectables industry. The deal will greatly strengthen Fosun Pharma’s global presence and accelerate our speed of internationalisation. It will enable us to provide more high-quality products and services to our patients worldwide. Fosun Pharma is dedicated to implementing our investment model of ‘Combining China’s Growth Momentum with Global Resources’ with the win-win cooperation with Gland.”
Simpson Thacher & Bartlett and Cyril Amarchand Mangaldas provided legal advice to KKR and Gland. Jefferies acted as exclusive financial advisor to Gland and KKR. The transaction is subject to customary regulatory approvals.
